Evidence map›Paper›PMID 29081684›Full record

ArticleSarcoma2017

Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.

Raymundo A Quintana, Jose Banchs, Ridhi Gupta, Heather Y Lin, Sean D Raj, Anthony Conley, Vinod Ravi, Dejka Araujo, Robert S Benjamin, Shreyaskumar Patel and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Raymundo A QuintanaDepartment of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1451, Houston, TX 77030, USA.ORCID 0000-0001-6430-4554
Jose BanchsDepartment of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1451, Houston, TX 77030, USA.ORCID 0000-0001-7375-2666
Ridhi GuptaDivision of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Heather Y LinDepartment of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1451, Houston, TX 77030, USA.
Sean D RajDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.
Anthony ConleyDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.
Vinod RaviDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.
Dejka AraujoDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.ORCID 0000-0002-1223-6542
Robert S BenjaminDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.ORCID 0000-0002-2589-5870
Shreyaskumar PatelDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.ORCID 0000-0002-0026-2348
Saroj Vadhan-RajDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.
Neeta SomaiahDepartment of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USMedical University of South Carolina · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

backgroundDespite the dose-dependent response rate of sarcomas to doxorubicin, clinicians limit its cumulative dose due to cardiotoxicity. This study evaluates early evidence of cardiotoxicity in patients treated with high-dose doxorubicin given as a continuous infusion.

methodsData was collected on patients who received 90 mg/m

resultOut of the 48 patients enrolled, no patient developed heart failure symptoms; however, 4 out of the 38 (10%) patients with serial left ventricular ejection fraction assessments developed subclinical cardiotoxicity (asymptomatic drop in LVEF ≥ 10%). Twenty-three patients received all six 72-hour cycles of doxorubicin with a mean cumulative dose of 540 mg/m

conclusionsDoxorubicin cardiotoxicity can be limited by administering doxorubicin as a continuous infusion, allowing higher cumulative dosing to maximize efficacy.

Identifiers

PMID29081684
PMCPMC5634608
OpenAlexW2758313541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.